Home
About
Why D4DPR?
Strategic Vision
Platform of Regulations
Leadership
D4DPR Experts
D4DPR Updates
Advocacy
Media
Expert Testimony
Coalition Partners
Education
Cannabis Curriculums
Regulation & Public Health
Harms of Prohibition
Myths, Risks & Uncertainties
Resources
Ask a Question
Regulation
Universal Cannabis Symbol
JOIN
DONATE
Home
Supporting Maryland’s Adult Use Cannabis Program (HB556)
Supporting Maryland’s Adult Use Cannabis Program (HB556)
Deondra Asike
Expert Testimony
|
February 16, 2023
|
Medical (cannabis)
Download PDF
</div><p></p></div><div class="socialshare blog"><div class="text-block-7"><strong>Share: </strong></div><div class="html-embed-7 w-embed"><a href="https://www.facebook.com/sharer/sharer.php?u=https%3A//dfcr.org/post/dfcrs-maryland-spokesperson-submits-written-testimony-for-general-assembly-committee-in-support-of-hb556" target="_blank" class="share-icon-wrap w-inline-block"><img loading="lazy" width="30" src="https://assets-global.website-files.com/6140f19dc034b9b282445f9c/6169a5996d25fba25b1aa18a_facebook.png" alt="" class="social-media-icons"></a></div><div class="html-embed-7 w-embed"><a href="https://twitter.com/intent/tweet?text=https%3A//dfcr.org/post/dfcrs-maryland-spokesperson-submits-written-testimony-for-general-assembly-committee-in-support-of-hb556" target="_blank" class="share-icon-wrap w-inline-block"><img loading="lazy" width="30" src="https://assets-global.website-files.com/6140f19dc034b9b282445f9c/6169a5997f7803a3b9c69bdd_twitter.png" alt="" class="social-media-icons"></a></div><div class="html-embed-7 w-embed"><a class="w-inline-block social-share-btn social-media-icons email" href="mailto:?subject=&body=:%20" target="_blank" title="Email" onclick="window.open('mailto:?subject=' + encodeURIComponent(document.title) + '&body=' + encodeURIComponent('https://dfcr.org/post/dfcrs-maryland-spokesperson-submits-written-testimony-for-general-assembly-committee-in-support-of-hb556')); return false;"><img loading="lazy" width="30" src="https://assets-global.website-files.com/6140f19dc034b9b282445f9c/6194228b96c3d141b17766c4_email-svgrepo-com.svg" alt="" class="social-media-icons"></a></div></div><div class="divider"></div></div><div><h2>About the Author</h2><div class="w-row"><div class="w-col w-col-1"><img alt="Deondra Asike" loading="lazy" width="140" src="https://assets-global.website-files.com/6140f19ec034b96f37445fa8/63e278e387ca3c83c689af9b_Deondra%20Asike%20Headshot.png" class="image-6"/></div><div class="w-col w-col-11"><h3>Deondra Asike</h3><div class="w-richtext"><p><a href="https://anesthesiology.hopkinsmedicine.org/faculty/deondra-asike/" target="_blank"><strong>Deondra Asike, MD</strong></a> is a board-certified anesthesiologist and pain medicine physician. She is a licensed acupuncturist and Clinical Associate at Johns Hopkins Hospital. Dr. Asike is a veteran of the United States Air Force and deployed to Bagram Airfield, Afghanistan in 2013. She received her BS in Physiological Sciences from the University of Arizona and medical degree at Georgetown University School of Medicine. She completed her anesthesiology residency at the San Antonio Military Medical Center and fellowship training in pain medicine at the University of Maryland. Dr. Asike currently serves on the Maryland Department of Health Prescription Drug Monitoring Program Advisory Board. She believes strongly in a multimodal approach to chronic pain management that includes non-opioid medications, cannabis as medicine, physical therapy, and behavioral therapy. In 2022, Dr. Asike founded <a href="https://nationalpainreleaf.com/" target="_blank">National Pain ReLEAF </a>to help reform the way we treat chronic pain while supporting the body’s own healing process.</p></div></div></div></div></div></div><div class="footer-section"><div class="content-section footer no-padding"><div class="container-wrapper-second footer"><div class="footer-block"><img src="https://assets-global.website-files.com/6140f19dc034b9b282445f9c/65170f78c8bbb4e95b23593d_D4DPR%20Horizonal%20Light%20Bkgrd.png" loading="lazy" width="286" sizes="(max-width: 479px) 83vw, (max-width: 767px) 41vw, (max-width: 991px) 29vw, (max-width: 1279px) 18vw, (max-width: 1919px) 222.21875px, 286px" alt="D4DPR logo" srcset="https://assets-global.website-files.com/6140f19dc034b9b282445f9c/65170f78c8bbb4e95b23593d_D4DPR%20Horizonal%20Light%20Bkgrd-p-500.png 500w, https://assets-global.website-files.com/6140f19dc034b9b282445f9c/65170f78c8bbb4e95b23593d_D4DPR%20Horizonal%20Light%20Bkgrd-p-800.png 800w, https://assets-global.website-files.com/6140f19dc034b9b282445f9c/65170f78c8bbb4e95b23593d_D4DPR%20Horizonal%20Light%20Bkgrd-p-1080.png 1080w, https://assets-global.website-files.com/6140f19dc034b9b282445f9c/65170f78c8bbb4e95b23593d_D4DPR%20Horizonal%20Light%20Bkgrd.png 1300w"/><div class="w-embed"><style> .image-container { text-align: center; } </style> <div class="image-container"> <a href="https://www.guidestar.org/profile/shared/ac11f4b2-d8c8-45e0-8006-58a23796b851" target="_blank"> <img src="https://widgets.guidestar.org/TransparencySeal/9511393" width="100" alt="Guidestar Transparency Seal"> </a> </div></div></div><div class="footer-block top"><h4 class="blog-tittle dark footer">Follow</h4><div class="div-block-25 w-clearfix"><a href="https://www.facebook.com/D4DPRorg/" Title="facebook" target="_blank" class="top-social-block second-version w-inline-block w-clearfix"><img src="https://assets-global.website-files.com/6140f19dc034b9b282445f9c/6169a5996d25fba25b1aa18a_facebook.png" width="54" alt="Facebook" class="top-nav-icon"/></a><a href="https://twitter.com/d4dprorg" Title="Twitter" target="_blank" class="top-social-block second-version w-inline-block w-clearfix"><img src="https://assets-global.website-files.com/6140f19dc034b9b282445f9c/6169a5997f7803a3b9c69bdd_twitter.png" width="49" alt="Twitter" class="top-nav-icon"/></a><a href="https://www.linkedin.com/company/d4dprorg/" Title="LinkedIn" target="_blank" class="top-social-block second-version w-inline-block w-clearfix"><img src="https://assets-global.website-files.com/6140f19dc034b9b282445f9c/6169a59a8bfa9732bf790b6e_linkedin.png" width="40" alt="LinkedIn" class="top-nav-icon"/></a><a href="https://www.instagram.com/d4dprorg/" Title="Instagram" target="_blank" class="top-social-block second-version w-inline-block w-clearfix"><img src="https://assets-global.website-files.com/6140f19dc034b9b282445f9c/6169a599335ab4511c5e6dd0_insta.png" width="53" alt="Instagram" class="top-nav-icon"/></a><a href="https://www.youtube.com/channel/UC7GLBo2PRDXuL8dzdQC2A3Q" Title="YouTube" target="_blank" class="top-social-block second-version w-inline-block w-clearfix"><img src="https://assets-global.website-files.com/6140f19dc034b9b282445f9c/6169a708d0c8a4bd4cf361c6_youtube-svgrepo-com%20(1).svg" width="56" alt="YouTube" class="top-nav-icon"/></a></div></div><div class="footer-block contact"><h4 class="blog-tittle dark footer">Contact Us</h4><p><a href="mailto:info@d4dpr.org">info@d4dpr.org</a></p><p>Phone: (202) 930-0097</p><p>Doctors for Drug Policy Reform<br/>712 H Street NE, Suite 1290<br/>Washington, DC 20002</p></div><div class="footer-block third"><h4 class="blog-tittle dark footer">D4DPR News & Events</h4><a href="https://d4dpr.org/updates/media" class="link-block w-inline-block"><div class="text-block-4">Media</div></a><a href="/expert-testimony" class="link-block w-inline-block"><div class="text-block-4">Expert Testimony</div></a><a href="https://d4dpr.org/updates/education" class="link-block w-inline-block"><div class="text-block-4">Education</div></a><a href="https://d4dpr.org/updates/dfcr" class="link-block w-inline-block"><div class="text-block-4">D4DPR Updates</div></a></div><div class="footer-block fourth"><h4 class="blog-tittle dark footer">Sign Up for Our Newsletter!</h4><div class="html-embed-4 w-embed w-iframe"><iframe src="https://d4dpr.dm.networkforgood.com/forms/102955?iframe=1" width="100%" height="380px" frameborder="0">
©2024 Doctors for Cannabis Regulation, LLC DBA Doctors for Drug Policy Reform. All rights reserved.
